Alkem Laboratories

₹5498 -7.9 | 0.1%

WEBSITE BSE:539523 NSE : ALKEM 09 Dec, 12:02

Market Cap ₹65737 Cr.

Stock P/E 36.3

P/B 5.7

Current Price ₹5498

Book Value ₹ 961.2

Face Value 2

52W High ₹6440

Dividend Yield 0.73%

52W Low ₹ 4409.9

Edit Ratio

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Limited is a pharmaceutical agency. The Company is engaged inside the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates via 2 segments: pharmaceutical and investing. The Company produces generics,generic drugs, APIs and neutraceuticals, which it markets in India and about 50 international locations across the world. The Company offers numerous products, which include CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, amongst others. The Company has approximately 16 production facilities, of which 14 manufacturing facilities are at geographically different places in India and within the United States.

Alkem Laboratories Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Alkem Laboratories Quarterly Results

#(Fig in Cr.)	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Net Sales	2576	3079	3041	2903	2968	3440	3324	2936	3032	3415
Other Income	51	51	45	69	66	63	94	88	120	134
Total Income	2628	3130	3086	2971	3034	3503	3418	3024	3152	3549
Total Expenditure	2373	2625	2442	2549	2579	2693	2616	2534	2423	2662
Operating Profit	255	505	644	422	455	810	801	490	729	887
Interest	27	25	27	29	30	30	25	27	29	28
Depreciation	76	77	78	78	72	74	70	83	80	79
Exceptional Income / Expenses	0	0	0	-103	0	-58	-51	-13	0	0
Profit Before Tax	152	402	539	212	353	648	655	367	619	780
Provision for Tax	20	55	79	144	65	33	51	63	69	78
Profit After Tax	131	348	460	68	288	615	604	304	550	702
Adjustments	-4	-17	-5	3	-1	6	-9	-11	-5	-13
Profit After Adjustments	128	331	455	71	287	621	595	294	545	689
Adjusted Earnings Per Share	10.7	27.7	38	5.9	24	51.9	49.8	24.6	45.6	57.6

Alkem Laboratories Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	3126	3743	4925	5688	6392	7357	8344	8865	10634	11599	12668	12707
Other Income	165	181	240	112	115	88	104	233	163	216	311	436
Total Income	3291	3924	5165	5800	6507	7445	8449	9098	10797	11815	12978	13143
Total Expenditure	2716	3322	4072	4689	5383	6242	6871	6923	8581	9990	10422	10235
Operating Profit	575	603	1093	1111	1124	1202	1578	2176	2216	1826	2556	2907
Interest	93	81	71	45	55	55	65	59	52	107	112	109
Depreciation	52	71	93	101	143	193	253	275	304	310	299	312
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	-15	-103	-121	-64
Profit Before Tax	430	451	928	965	926	955	1260	1842	1844	1305	2023	2421
Provision for Tax	-5	59	176	60	288	181	110	224	164	298	212	261
Profit After Tax	435	392	752	905	638	774	1149	1618	1680	1007	1811	2160
Adjustments	0	0	-11	-13	-7	-13	-22	-33	-35	-23	-16	-38
Profit After Adjustments	435	392	742	892	631	761	1127	1585	1646	984	1796	2123
Adjusted Earnings Per Share	36.4	32.8	62	74.6	52.8	63.6	94.3	132.6	137.7	82.3	150.2	177.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	9%	13%	11%	15%
Operating Profit CAGR	40%	6%	16%	16%
PAT CAGR	80%	4%	19%	15%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	17%	17%	21%	NA%
ROE Average	19%	17%	19%	18%
ROCE Average	20%	17%	19%	18%

Alkem Laboratories Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	2585	2999	3692	4468	4864	5439	6161	7377	8638	9045	10312
Minority's Interest	0	86	95	115	122	133	148	181	209	390	402
Borrowings	232	33	123	182	131	231	74	28	9	0	40
Other Non-Current Liabilities	92	167	-430	-582	-489	-520	-614	-779	-902	-688	-689
Total Current Liabilities	1403	2006	1538	1690	2383	2218	3245	3604	4805	3707	3995
Total Liabilities	4311	5291	5018	5872	7010	7501	9013	10411	12760	12454	14060
Fixed Assets	1170	1374	1450	1797	2284	2530	2908	2793	2902	2683	2873
Other Non-Current Assets	1539	1579	800	1158	713	754	599	690	1423	1042	776
Total Current Assets	1602	2338	2769	2915	4013	4204	5488	6923	8434	8606	10412
Total Assets	4311	5291	5018	5872	7010	7501	9013	10411	12760	12454	14060

Alkem Laboratories Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	57	101	124	127	167	167	249	176	174	232	274
Cash Flow from Operating Activities	290	325	726	471	266	780	585	1265	1111	1683	1948
Cash Flow from Investing Activities	350	-237	202	-286	-357	-316	-741	-999	-1435	113	-1009
Cash Flow from Financing Activities	-600	-52	-927	-138	85	-379	79	-272	380	-1761	-1145
Net Cash Inflow / Outflow	41	37	1	47	-7	84	-77	-5	55	35	-205
Closing Cash & Cash Equivalent	101	140	127	167	167	249	176	174	232	274	66

Alkem Laboratories Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	36.4	32.76	62.03	74.62	52.78	63.61	94.28	132.58	137.65	82.32	150.21
CEPS(Rs)	40.77	38.69	70.73	84.14	65.37	80.87	117.28	158.29	165.98	110.18	176.56
DPS(Rs)	4	4	12.7	15	13	16	25	30	34	50	40
Book NAV/Share(Rs)	216.13	250.86	308.82	373.67	406.76	454.86	515.21	616.95	722.48	756.56	860.94
Core EBITDA Margin(%)	12.66	10.93	16.9	17.07	11.76	10.41	11.89	14.82	13.44	8.97	11.58
EBIT Margin(%)	16.15	13.78	19.8	17.25	11.43	9.42	10.69	14.5	12.42	7.87	11.02
Pre Tax Margin(%)	13.28	11.68	18.39	16.48	10.79	8.91	10.16	14.05	12.07	7.27	10.44
PAT Margin (%)	13.44	10.15	14.9	15.46	7.44	7.22	9.27	12.34	11	5.61	9.35
Cash Profit Margin (%)	15.06	11.98	16.75	17.19	9.1	9.03	11.31	14.43	12.99	7.34	10.89
ROA(%)	10.14	8.16	14.59	16.61	9.91	10.66	13.92	16.66	14.5	7.99	13.66
ROE(%)	18.28	14.03	22.48	22.18	13.69	15.02	19.82	23.91	20.99	11.39	18.74
ROCE(%)	14.06	13.27	23.1	21.31	17.86	16.49	18.71	22.56	18.69	13.09	19.52
Receivable days	38.62	42.27	39.57	39.95	38.15	39.69	42.66	45.33	41.72	40.86	41.28
Inventory Days	66.19	66.41	61.23	65.96	56.31	50.14	48.86	57.51	63.54	57.1	49.6
Payable days	92.7	96.89	117.1	133.45	156.37	135.69	118.18	118.18	114.79	97.4	122.87
PER(x)	0	0	22.03	29.58	37.46	27.54	24.7	20.91	26.28	41.27	32.89
Price/Book(x)	0	0	4.42	5.91	4.86	3.85	4.52	4.49	5.01	4.49	5.74
Dividend Yield(%)	0	0	0.93	0.68	0.66	0.91	1.07	1.08	0.94	1.47	0.81
EV/Net Sales(x)	0.3	0.14	3.29	4.68	3.76	2.88	3.4	3.71	4.07	3.39	4.63
EV/Core EBITDA(x)	1.62	0.89	14.83	23.98	21.4	17.65	17.98	15.1	19.52	21.53	22.96
Net Sales Growth(%)	25.28	19.75	31.56	15.49	12.38	15.1	13.42	6.24	19.96	9.08	9.21
EBIT Growth(%)	6.78	1.7	87.93	1.01	-2.82	2.85	31.27	43.49	-0.23	-25.55	51.23
PAT Growth(%)	13.47	-10.05	92.1	20.27	-29.43	21.18	48.56	40.76	3.87	-40.08	79.92
EPS Growth(%)	13.42	-10.01	89.38	20.29	-29.27	20.54	48.2	40.63	3.82	-40.19	82.47
Debt/Equity(x)	0.44	0.44	0.18	0.15	0.21	0.17	0.26	0.23	0.3	0.14	0.12
Current Ratio(x)	1.14	1.17	1.8	1.73	1.68	1.9	1.69	1.92	1.76	2.32	2.61
Quick Ratio(x)	0.7	0.77	1.21	1.01	1.08	1.22	1.13	1.28	1.13	1.62	1.94
Interest Cover(x)	5.62	6.56	14.03	22.36	17.74	18.48	20.36	32.26	36.22	13.15	19
Total Debt/Mcap(x)	0	0	0.04	0.02	0.04	0.05	0.06	0.05	0.06	0.03	0.02

Alkem Laboratories Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	57.14	57.16	57.16	57.16	57.16	56.74	56.74	56.74	56.38	55.66
FII	5.67	4.46	4.41	4.44	5.64	6.03	8.49	9.11	8.69	9.02
DII	14.1	15.74	16.44	16.69	16.34	17.64	15.91	15.63	18.57	19.21
Public	23.09	22.65	21.99	21.7	20.86	19.59	18.86	18.52	16.36	16.1
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	6.83	6.83	6.83	6.83	6.83	6.78	6.78	6.78	6.74	6.66
FII	0.68	0.53	0.53	0.53	0.67	0.72	1.01	1.09	1.04	1.08
DII	1.69	1.88	1.97	2	1.95	2.11	1.9	1.87	2.22	2.3
Public	2.76	2.71	2.63	2.59	2.49	2.34	2.26	2.21	1.96	1.93
Others	0	0	0	0	0	0	0	0	0	0
Total	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96

Pros

Company is almost debt free.

Cons

Debtor days have increased from 97.4 to 122.87days.
Stock is trading at 5.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alkem Laboratories News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Alkem Laboratories

Add Watchlist

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Share Price

Alert Data

Quarterly Price

Peer Comparison

Alkem Laboratories Quarterly Results

Alkem Laboratories Profit & Loss

Growth Rates

Alkem Laboratories Balance Sheet

Alkem Laboratories Cash Flow

Alkem Laboratories Ratios

Alkem Laboratories Shareholding Pattern

Alkem Laboratories News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!